ELSEVIER

Atherosclerosis 132 (1997) 261–263

atherosclerosis

Author index

Volume 132 (1997)

Agerholm-Larsen, B., see Nordestgaard, B.G. **132**, 119
Amakawa, M., see Fukui, R. **132**, 53
Amy, R.M., see Russell, J.C. **132**, 187
Angeli, A., see Ragogna, F. **132**, 157
Anthony, M., see Hannah, J.S. **132**, 19
Aoki, T., see Takahashi, J.C. **132**, 199
Aston, C.E., see Pasagian-Macaulay, A. **132**, 221

Beaudeux, J.-L., M.-L. Césarini, M. Gardès-Albert, J. Maclouf, R. Merval, B. Esposito, J. Peynet, A. Tedgui, Native and γ radiolysis-oxidized lipoprotein(a) increase the adhesiveness of rabbit aortic endothelium **132**, 29
Blangero, J., see Rainwater, D.L. **132**, 237
Blann, A.D., J.P. Miller, C.N. McCollum, von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia **132**, 151
Blom, H.J., see Verhoef, P. **132**, 105
Bolinder, G., A. Norén, U. de Faire, J. Wahren, Smokeless tobacco use and atherosclerosis: an ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men **132**, 95
Bowyer, D.E., see Torzewski, J. **132**, 131
Brindley, D.N., see Russell, J.C. **132**, 187

Cambier, B., see Delanghe, J. **132**, 215
Camejo, G., see Hurt-Camejo, E. **132**, 1
Campbell, G.R., see Efendy, J.L. **132**, 37
Campbell, J.H., see Efendy, J.L. **132**, 37
Césarini, M.-L., see Beaudeux, J.-L. **132**, 29
Cohn, J.S., see Giroux, L.-M. **132**, 85
Comuzzie, A.G., see Rainwater, D.L. **132**, 237
Corazza, S., see Ragogna, F. **132**, 157
Cupples, L.A., see Kauppila, L.I. **132**, 245

Davignon, J., see Giroux, L.-M. **132**, 85
De Bacquer, D., see Delanghe, J. **132**, 215
De Buyzere, M., see Delanghe, J. **132**, 215
de Faire, U., see Bolinder, G. **132**, 95
de Jong-Caesar, R., see van Tol, A. **132**, 251
Delanghe, J., B. Cambier, M. Langlois, M. De Buyzere, H. Neels, D. De Bacquer, P. Van Cauwelaert, Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery **132**, 215
de Roos, B., see van Tol, A. **132**, 251
Doi, Y., M. Yoshinari, H. Yoshizumi, S. Ibayashi, M. Wakisaka, M. Fujishima, Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction **132**, 145
Dolphin, P.J., see Russell, J.C. **132**, 187

Eckey, R., M. Menschikowski, P. Lattke, W. Jaross, Minimal oxidation and storage of low density lipoproteins result in an increased susceptibility to phospholipid hydrolysis by phospholipase A_2 **132**, 165
Efendy, J.L., D.L. Simmons, G.R. Campbell, J.H. Campbell, The effect of the aged garlic extract, 'Kyolic', on the development of experimental atherosclerosis **132**, 37
Esposito, B., see Beaudeux, J.-L. **132**, 29

Fabian, A.J., see Upchurch, G.R., Jr **132**, 177
Faergeman, O., see Klausen, I.C. **132**, 77
Faggiotto, A., see Ragogna, F. **132**, 157
Ferrell, R.E., see Pasagian-Macaulay, A. **132**, 221
Fischer Hansen, B., see Nordestgaard, B.G. **132**, 119
Fischer Hansen, J., see Nordestgaard, B.G. **132**, 119
Fitzsimmons, C., see Torzewski, J. **132**, 131
Fujishima, M., see Doi, Y. **132**, 145
Fukui, R., N. Shibata, E. Kohbayashi, M. Amakawa, D. Furutama, M. Hoshiga, N. Negoro, T. Nakakouji, M. Ii, T. Ishihara, N. Ohsawa, Inhibition of smooth muscle cell migration by the p21 cyclin-dependent kinase inhibitor (Cip1) **132**, 53
Funahashi, T., see Yanagi, K. **132**, 43
Furutama, D., see Fukui, R. **132**, 53

Gardès-Albert, M., see Beaudeux, J.-L. **132**, 29
Gerdes, L.U., see Klausen, I.C. **132**, 77
Giroux, L.-M., J.S. Cohn, J. LaMarre, J. Davignon, Pseudo type III dyslipoproteinemia is associated with normal fibroblast lipoprotein receptor activity **132**, 85
González-Sastre, F., see Sánchez-Quesada, J.L. **132**, 207
Goto, K., see Takahashi, J.C. **132**, 199
Graham, S.E., see Russell, J.C. **132**, 187
Grassi, A., see Ragogna, F. **132**, 157
Groenen-van Dooren, M.M.C.L., see Ronden, J.E. **132**, 61

Hannah, J.S., K. Yamane, S. Kataoka, M. Anthony, B.V. Howard, High fat, high cholesterol diets alter low density lipoprotein size and binding affinity in monkeys **132**, 19
Hannan, M.T., see Kauppila, L.I. **132**, 245
Hansen, P.S., see Klausen, I.C. **132**, 77
Haraki, T., A. Inazu, K. Yagi, K. Kajinami, J. Koizumi, H. Mabuchi, Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency **132**, 229
Hornstra, G., see Ronden, J.E. **132**, 61
Hoshiga, M., see Fukui, R. **132**, 53
Howard, B.V., see Hannah, J.S. **132**, 19
Hurt-Camejo, E., G. Camejo, Potential involvement of type II phospholipase A_2 in atherosclerosis **132**, 1

Ibayashi, S., see Doi, Y. **132**, 145
Ibsen, P., see Nordestgaard, B.G. **132**, 119
Ii, M., see Fukui, R. **132**, 53
Inazu, A., see Haraki, T. **132**, 229
Ishihara, T., see Fukui, R. **132**, 53
Iwakami, M., see Oniki, T. **132**, 115

Jaross, W., see Eckey, R. **132**, 165
Jiao, S., see Yanagi, K. **132**, 43

Kajinami, K., see Haraki, T. **132**, 229
Kameda-Takemura, K., see Yanagi, K. **132**, 43
Kanzaki, T., see Tamura, K. **132**, 139
Katan, M.B., see van Tol, A. **132**, 251
Kataoka, S., see Hannah, J.S. **132**, 19
Kauppila, L.I., J.F. Polak, L.A. Cupples, M.T. Hannan, D.P. Kiel, P.W.F. Wilson, New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study **132**, 245
Keaney, J.F., Jr, see Upchurch, G.R., Jr **132**, 177
Kiel, D.P., see Kauppila, L.I. **132**, 245
Kihara, S., see Yanagi, K. **132**, 43
Kikuchi, H., see Takahashi, J.C. **132**, 199
Kjeldsen, K., see Nordestgaard, B.G. **132**, 119
Klausen, I.C., A. Sjøl, P.S. Hansen, L.U. Gerdes, L. Møller, L. Lemming, M. Schroll, O. Faergeman, Apolipoprotein(a) isoforms and coronary heart disease in men : A nested case-control study **132**, 77
Kluijtmans, L.A.J., see Verhoef, P. **132**, 105
Kohbayashi, E., see Fukui, R. **132**, 53
Koizumi, J., see Haraki, T. **132**, 229
Kok, F.J., see Verhoef, P. **132**, 105
Kruyssen, D.A.C.M., see Verhoef, P. **132**, 105
Kubo, H., see Takahashi, J.C. **132**, 199
Kubo, M., see Yanagi, K. **132**, 43
Kuller, L.H., see Pasagian-Macaulay, A. **132**, 221

LaMarre, J., see Giroux, L.-M. **132**, 85
Langlois, M., see Delanghe, J. **132**, 215
Lasunción, M.A., see Sánchez-Quesada, J.L. **132**, 207
Lattke, P., see Eckey, R. **132**, 165
Lemming, L., see Klausen, I.C. **132**, 77
Loscalzo, J., see Upchurch, G.R., Jr **132**, 177
Luley, C., see Özçürümez, M. **132**, 255

Mabuchi, H., see Haraki, T. **132**, 229
Maclouf, J., see Beaudeux, J.-L. **132**, 29
Mahaney, M.C., see Rainwater, D.L. **132**, 237
Matsuzawa, Y., see Yanagi, K. **132**, 43
McAllister, A.E., see Pasagian-Macaulay, A. **132**, 221
McCollum, C.N., see Blann, A.D. **132**, 151
Menschikowski, M., see Eckey, R. **132**, 165
Merval, R., see Beaudeux, J.-L. **132**, 29
Miller, J.P., see Blann, A.D. **132**, 151
Miyatake, S.-I., see Takahashi, J.C. **132**, 199
Møller, L., see Klausen, I.C. **132**, 77
Morisaki, N., see Tamura, K. **132**, 139
Mortensen, A., see Nordestgaard, B.G. **132**, 119
Murata, A., see Murata, K. **132**, 9
Murata, K., A. Murata, K. Yoshida, Heparan sulfate isomers in cerebral arteries of Japanese women with aging and with atherosclerosis—heparitinase and high-performance liquid chromatography determinations **132**, 9

Nagai, Y., see Yanagi, K. **132**, 43
Nagata, I., see Takahashi, J.C. **132**, 199
Nakakouji, T., see Fukui, R. **132**, 53
Nakamura, T., see Yanagi, K. **132**, 43
Nauck, M., see Özçürümez, M. **132**, 255
Neels, H., see Delanghe, J. **132**, 215
Negoro, N., see Fukui, R. **132**, 53
Nordestgaard, B.G., B. Agerholm-Larsen, A. Mortensen, B. Fischer Hansen, J. Fischer Hansen, P. Ibsen, K. Kjeldsen, Intermediate density lipoprotein cholesterol as the best lipoprotein predictor of atherosclerosis severity in the Watanabe Heritable Hyperlipidemic rabbit **132**, 119
Norén, A., see Bolinder, G. **132**, 95
Nozaki, S., see Yanagi, K. **132**, 43

Ohsawa, N., see Fukui, R. **132**, 53
Oniki, T., M. Iwakami, Is arterial remodeling truly a compensatory biological reaction? : A mechanical deformation hypothesis **132**, 115
Ordóñez-Llanos, J., see Sánchez-Quesada, J.L. **132**, 207
Ortega, H., see Sánchez-Quesada, J.L. **132**, 207
Otabe, M., see Tamura, K. **132**, 139
Özçürümez, M., S. Westphal, M. Nauck, H. Wieland, C. Luley, Importance of apo E2 heterozygosity, insulin, and hypertriglyceridemia for very low density lipoproteins **132**, 255

Pasagian-Macaulay, A., C.E. Aston, R.E. Ferrell, A.E. McAllister, R.R. Wing, L.H. Kuller, A dietary and behavioral intervention designed to lower coronary heart disease. Risk factors are unaffected by variation at the APOE gene locus **132**, 221
Payés-Romero, A., see Sánchez-Quesada, J.L. **132**, 207
Peynet, J., see Beaudeux, J.-L. **132**, 29
Pigazzi, A., see Upchurch, G.R., Jr **132**, 177
Polak, J.F., see Kauppila, L.I. **132**, 245
Prasad, K., Dietary flax seed in prevention of hypercholesterolemic atherosclerosis **132**, 69

Ragogna, F., A. Angeli, S. Corazza, C. Tettamanti, A. Faggiotto, A. Grassi, G. Ruotolo, Increased J774 macrophage cytotoxicity of late postprandial triglyceride-rich lipoproteins from normolipidemic young men expressing an apolipoprotein ε4 allele **132**, 157
Rainwater, D.L., A.G. Comuzzie, J.L. VandeBerg, M.C. Mahaney, J. Blangero, Serum leptin levels are independently correlated with two measures of HDL **132**, 237
Refsum, H., see Verhoef, P. **132**, 105
Ronden, J.E., M.M.C.L. Groenen-van Dooren, G. Hornstra, C. Vermeer, Modulation of arterial thrombosis tendency in rats by vitamin K and its side chains **132**, 61
Ruotolo, G., see Ragogna, F. **132**, 157
Russell, J.C., S.E. Graham, P.J. Dolphin, R.M. Amy, G.O. Wood, D.N. Brindley, Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats **132**, 187

Saiki, M., see Takahashi, J.C. **132**, 199
Saito, Y., see Tamura, K. **132**, 139
Saito, Y., see Tamura, K. **132**, 139
Sánchez-Quesada, J.L., H. Ortega, A. Payés-Romero, J. Serrat-Serrat, F. González-Sastre, M.A. Lasunción, J. Ordóñez-Llanos, LDL from aerobically-trained subjects shows higher resistance to oxidative modification than LDL from sedentary subjects **132**, 207
Scheek, L.M., see van Tol, A. **132**, 251
Schroll, M., see Klausen, I.C. **132**, 77
Serrat-Serrat, J., see Sánchez-Quesada, J.L. **132**, 207
Shibata, N., see Fukui, R. **132**, 53
Simmons, D.L., see Efendy, J.L. **132**, 37
Sjøl, A., see Klausen, I.C. **132**, 77

Takahashi, J.A., see Takahashi, J.C. **132**, 199

Takahashi, J.C., M. Saiki, S.-I. Miyatake, S. Tani, H. Kubo, K. Goto, T. Aoki, J.A. Takahashi, I. Nagata, H. Kikuchi, Adenovirus-mediated gene transfer of basic fibroblast growth factor induces in vitro angiogenesis **132**, 199
Tamura, K., T. Kanzaki, Y. Saito, M. Otabe, Y. Saito, N. Morisaki, Serotonin (5-hydroxytryptamine, 5-HT) enhances migration of rat aortic smooth muscle cells through 5-HT_2 receptors **132**, 139
Tani, S., see Takahashi, J.C. **132**, 199
Tedgui, A., see Beaudeux, J.-L. **132**, 29
Tettamanti, C., see Ragogna, F. **132**, 157
Tokunaga, K., see Yanagi, K. **132**, 43
Torzewski, J., D.E. Bowyer, J. Waltenberger, C. Fitzsimmons, Processes in atherogenesis: complement activation **132**, 131

Ueland, P.M., see Verhoef, P. **132**, 105
Ueyama, Y., see Yanagi, K. **132**, 43
Upchurch, G.R., Jr, G.N. Welch, A.J. Fabian, A. Pigazzi, J.F. Keaney, Jr, J. Loscalzo, Stimulation of endothelial nitric oxide production by homocyst(e)ine **132**, 177
Urgert, R., see van Tol, A. **132**, 251

Van Cauwelaert, P., see Delanghe, J. **132**, 215
VandeBerg, J.L., see Rainwater, D.L. **132**, 237
van Gent, T., see van Tol, A. **132**, 251
van Tol, A., R. Urgert, R. de Jong-Caesar, T. van Gent, L.M. Scheek, B. de Roos, M.B. Katan, The cholesterol-raising diterpenes from coffee beans increase serum lipid transfer protein activity levels in humans **132**, 251
Verhoef, P., F.J. Kok, L.A.J. Kluijtmans, H.J. Blom, H. Refsum, P.M. Ueland, D.A.C.M. Kruyssen, The 677C→T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease **132**, 105
Vermeer, C., see Ronden, J.E. **132**, 61

Wahren, J., see Bolinder, G. **132**, 95
Wakisaka, M., see Doi, Y. **132**, 145
Waltenberger, J., see Torzewski, J. **132**, 131
Welch, G.N., see Upchurch, G.R., Jr **132**, 177
Westphal, S., see Özçürümez, M. **132**, 255
Wieland, H., see Özçürümez, M. **132**, 255
Wilson, P.W.F., see Kauppila, L.I. **132**, 245
Wing, R.R., see Pasagian-Macaulay, A. **132**, 221
Wood, G.O., see Russell, J.C. **132**, 187

Yagi, K., see Haraki, T. **132**, 229
Yamane, K., see Hannah, J.S. **132**, 19
Yamashita, S., see Yanagi, K. **132**, 43
Yanagi, K., S. Yamashita, S. Kihara, T. Nakamura, S. Nozaki, Y. Nagai, T. Funahashi, K. Kameda-Takemura, Y. Ueyama, S. Jiao, M. Kubo, K. Tokunaga, Y. Matsuzawa, Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance **132**, 43
Yoshida, K., see Murata, K. **132**, 9
Yoshinari, M., see Doi, Y. **132**, 145
Yoshizumi, H., see Doi, Y. **132**, 145

ELSEVIER

Atherosclerosis 132 (1997) 264–265

atherosclerosis

Subject index

Volume 132 (1997)

Acute myocardial infarction **132**, 215
Adenovirus **132**, 199
Adhesion **132**, 53
Aerobic exercise **132**, 207
Aging **132**, 145
Angiogenesis **132**, 199
Angiotensin converting enzyme **132**, 145
Antioxidants **132**, 207
Anti-platelet-activating factor **132**, 69
Aortic calcification **132**, 245
Apo E **132**, 255
Apo E lipoprotein **132**, 221
Apo E polymorphism **132**, 157
Apolipoprotein(a) **132**, 77
Apolipoprotein B **132**, 77
Arterial enlargement **132**, 115
Arterial obstruction **132**, 115
Atherosclerosis **132**, 1, 9, 69, 95, 115, 131, 151, 165, 187, 215, 245

Basic fibroblast growth factor **132**, 199
Benfluorex **132**, 187
Binding **132**, 19
Bradykinin **132**, 177

Cafestol **132**, 251
Calcium ionophore **132**, 177
C5b-9 **132**, 131
Cell adhesion **132**, 29
Cerebral thrombosis **132**, 145
CETP **132**, 251
Cholesterol **132**, 77, 151, 221
Cholesteryl ester transfer protein deficiency **132**, 229
Coagulation **132**, 61
Coffee **132**, 251
Complement activation **132**, 131
Coronary artery bypass grafting **132**, 215
Coronary artery disease **132**, 43
Coronary atherosclerosis **132**, 105
Coronary heart disease **132**, 77, 229

Diabetes mellitus **132**, 43
Dietary fats **132**, 19
Diterpenes **132**, 251
Double heterozygote **132**, 229

Endothelial cells **132**, 151, 199
Endothelium **132**, 29
Epidemiological study **132**, 245
Experimental atherosclerosis **132**, 37

Familial hypercholesterolemia **132**, 43, 119, 229
Flax lignans **132**, 69
Flax seed **132**, 69
Folate status **132**, 105
Free fatty acid **132**, 157
Free fatty acids **132**, 1

Garlic **132**, 37
Gene transfer **132**, 199
GGE **132**, 237
Glycosaminoglycans **132**, 9

Haptoglobin **132**, 215
HDL **132**, 237
HDL cholesterol **132**, 151
Heparan sulfates **132**, 9
Heparin **132**, 9
High-performance liquid chromatography **132**, 9
Homocysteine **132**, 105, 177
Homocystine **132**, 177
Human cerebral artery **132**, 9
Hypercholesterolemia **132**, 69
Hyperinsulinemia **132**, 255
Hypertriglyceridemia **132**, 255

Insulin resistance **132**, 187
Interleukin-1 **132**, 69

JCR:LA-cp rat **132**, 187

Kahweol **132**, 251
Kyolic **132**, 37

LCAT **132**, 251
LDL cholesterol **132**, 151
LDL susceptibility to oxidation **132**, 207
Leptin **132**, 237
Leukotriene B_4 **132**, 69
α-Linolenic acid **132**, 69
Lipid oxidation **132**, 165
Lipid transfer proteins **132**, 251
Lipolysis-stimulated receptor **132**, 85
Lipoprotein(a) **132**, 77
Lipoprotein receptor-related protein **132**, 85
Low density lipoprotein **132**, 19, 119, 165
Low-density lipoprotein receptor **132**, 85
Lp(a) **132**, 151
Lysophospholipids **132**, 1

Macrophages **132**, 157
Membrane attack complex **132**, 131
Menaquinone **132**, 61
Methylenetetrahydrofolate reductase **132**, 105
Migration **132**, 53, 139
Missense mutation **132**, 105
Monocytes **132**, 29
Multivariate genetic analysis **132**, 237
Myocardial infarction **132**, 77
Myocardial lesions **132**, 187

Nicotine **132**, 95
Nitric oxide **132**, 177
Nutrition **132**, 61

Obesity **132**, 237
Oxidized lipoprotein(a) **132**, 29
Oxidized low density lipoprotein **132**, 29
Oxygen radical producing activity of polymorphonuclear leukocytes **132**, 69

Particle size **132**, 255
$p21^{Cip1}$ **132**, 53
Phosphatidylinositol turnover **132**, 139
Phospholipase A_2 **132**, 165
Phospholipids **132**, 1
Phylloquinone **132**, 61
PLTP **132**, 251
Polymorphism **132**, 215
Postprandial lipoproteins **132**, 119, 157
Premenopausal **132**, 221
Pseudo type III dyslipoproteinemia **132**, 85

Remnant lipoproteins **132**, 43
Risk factors **132**, 95

Serotonin **132**, 139
Smokeless tobacco **132**, 95
Smooth muscle cells **132**, 53, 139
Soluble E-selectin **132**, 151

Thrombosis **132**, 61
Triglycerides **132**, 151
Tumor necrosis factor **132**, 69
Type II phospholipase A_2 **132**, 1

Ultrasonography **132**, 95

Vitamin K **132**, 61
VLDL **132**, 255
von Willebrand factor **132**, 151

Weight **132**, 221